RxDoctor Payments Data

Jeffrey Winston, MD

Psychiatry · Atlanta, GANPI 1003938598

Payments from drug & device makers

$16,297in general payments, 2019–2025

Across 823 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Lundbeck LLC$1K
  • Axsome Therapeutics, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Supernus Pharmaceuticals, Inc.$1K
  • plus $8K from 29 others

What the payments were for

  • Food & beverage$16,12699%
  • Education$1711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,297 in reported general payments places this provider in the 90th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$104,068
Medicare patients
116
Services billed
1,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$25,167
RexultiBrexpiprazole15$24,880
LybalviOlanzapine/Samidorphan Malate15$22,770
ConcertaMethylphenidate Hcl25$11,845
VyvanseLisdexamfetamine Dimesylate20$7,766
Aripiprazole104$4,353
Lurasidone Hcl17$3,802
Divalproex Sodium ErDivalproex Sodium52$3,421
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$3,330
Venlafaxine Hcl ErVenlafaxine Hcl71$3,174
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine129$3,027
Bupropion XlBupropion Hcl202$2,921
Acamprosate Calcium15$2,733
Duloxetine Hcl126$2,163
Alprazolam310$1,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,809$25,16718 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,682$24,88015 claims
Alkermes, Inc.Lybalvi$573$22,77015 claims
Johnson & JohnsonConcerta$1,022$11,84525 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$1,250$7,76620 claims
Almatica Pharma LLCSertraline Hcl$321$54465 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →